

The Pancreas, the Bile Duct, and Beyond: Exploring a New Treatment Option for IgG4-Related Disease

DDW SATELLITE SYMPOSIUM

**Saturday,
May 3, 2025**

6:00 PM–7:00 PM PT
Dinner will be provided

Omni San Diego Hotel
Grand Ballroom, Salon AB
San Diego, CA

Moderators



Emma Culver, MD, PhD
Consultant Hepatologist
and Clinical Lecturer
University of Oxford
Oxford, UK




Phil A. Hart, MD
Professor of Medicine
The Ohio State University
Wexner Medical Center
Columbus, OH

Objectives

- Highlight expert perspectives on diagnosing IgG4-RD and its manifestations, including type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis
- Review importance of assessing patients with IgG4-RD for extra-GI manifestations and role of co-management
- Showcase clinical trial data for an emerging treatment option for IgG4-RD

The Pancreas Is the Most Commonly Affected Organ in IgG4-RD, and Many Patients Also Have Biliary Involvement^{1,3}



The satellite symposium content and views expressed therein are those of the sponsor and not of Digestive Disease Week®.

1. Perugino, et al. *Nat Rev Rheumatol*. 2020;16:702-714. 2. Wallace, et al. *Arthritis Rheumatol*. 2016;68:2283-2289. 3. Miyabe, et al. *Gastroenterology*. 2018;155:990-1003. 4. Kawano, et al. *Mod Rheumatol*. 2023;33:242-251. 5. Stone, et al. *N Engl J Med*. 2012;366:539-551.
© 2025 Amgen Inc. All rights reserved. USA-335-80450 03/25

AMGEN 
Rare Disease